These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Phosphodiesterase 5 inhibitors for erectile dysfunction. Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818 [TBL] [Abstract][Full Text] [Related]
4. Pharmacology of erectile dysfunction in man. Cirino G; Fusco F; Imbimbo C; Mirone V Pharmacol Ther; 2006 Aug; 111(2):400-23. PubMed ID: 16443277 [TBL] [Abstract][Full Text] [Related]
5. Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical review. Rambhatla A; Kovanecz I; Ferrini M; Gonzalez-Cadavid NF; Rajfer J Int J Impot Res; 2008; 20(1):30-4. PubMed ID: 17673932 [TBL] [Abstract][Full Text] [Related]
6. Pharmacology of phosphodiesterase 5 inhibitors. Carrier S Can J Urol; 2003 Feb; 10 Suppl 1():12-6. PubMed ID: 12625845 [TBL] [Abstract][Full Text] [Related]
7. PDE5 inhibitors: are there differences? Carson CC Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979 [TBL] [Abstract][Full Text] [Related]
8. The evolving role of testosterone in the treatment of erectile dysfunction. Shabsigh R; Rajfer J; Aversa A; Traish AM; Yassin A; Kalinchenko SY; Buvat J Int J Clin Pract; 2006 Sep; 60(9):1087-92. PubMed ID: 16939550 [TBL] [Abstract][Full Text] [Related]
9. [New treatment options for erectile dysfunction. Pharmacologic and nonpharmacologic options]. Sperling H; Lümmen G; Schneider T; Rübben H Herz; 2003 Jun; 28(4):314-24. PubMed ID: 12825147 [TBL] [Abstract][Full Text] [Related]
10. [Update of PDE5 inhibitors for the treatment of ischemia-reperfusion]. Hu YY; Wu ZG Zhonghua Nan Ke Xue; 2011 Sep; 17(9):842-6. PubMed ID: 21961251 [TBL] [Abstract][Full Text] [Related]
11. Newer phosphodiesterase inhibitors: comparison with established agents. McNamara ER; Donatucci CF Urol Clin North Am; 2011 May; 38(2):155-63. PubMed ID: 21621082 [TBL] [Abstract][Full Text] [Related]
12. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials. Blonde L Curr Med Res Opin; 2006 Nov; 22(11):2111-20. PubMed ID: 17076971 [TBL] [Abstract][Full Text] [Related]
13. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Wright PJ Int J Clin Pract; 2006 Aug; 60(8):967-75. PubMed ID: 16780568 [TBL] [Abstract][Full Text] [Related]
14. [Whole rehabilitation: a new goal of erectile dysfunction therapy]. Zhang K Zhonghua Nan Ke Xue; 2006 Sep; 12(9):832-5. PubMed ID: 17009539 [TBL] [Abstract][Full Text] [Related]
15. [Update of PDE5 inhibitors as treatment of ED]. Lu YN; Chen B Zhonghua Nan Ke Xue; 2005 Jul; 11(7):552-5. PubMed ID: 16078679 [TBL] [Abstract][Full Text] [Related]
16. [Novel indications for phosphodiesterase type 5 inhibitors]. Rosenkranz S; Caglayan E; Erdmann E Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice. Ali ST Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424 [TBL] [Abstract][Full Text] [Related]
18. The therapeutic dilemma: how to use short-acting PDE5 inhibitor drugs. Fabbri A; Aversa A Int J Androl; 2005 Dec; 28 Suppl 2():69-73. PubMed ID: 16236069 [TBL] [Abstract][Full Text] [Related]
19. Sildenafil for erectile dysfunction. Drug Ther Bull; 1998 Nov; 36(11):81-4. PubMed ID: 10562764 [TBL] [Abstract][Full Text] [Related]
20. Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors. Hellstrom WJ Int J Clin Pract; 2007 Sep; 61(9):1547-54. PubMed ID: 17655683 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]